Company intelligence / Profile preview

DNAPro

Kuala Lumpur, Malaysia

Ownership: Private
Development stage: Other

Overview

DNAPro is a Malaysian biopharmaceutical company specializing in the manufacturing and trading of vaccines and specialty healthcare products. The company is a significant supplier to the Malaysian government and private sector, with a portfolio that includes recombinant Hepatitis B vaccines and development programs for anti-cancer and anti-AIDS therapeutics. DNAPro gained international visibility through a strategic investment from CyGenics (now Cordlife) and a joint venture with DNAPrint Genomics focused on pharmacogenomics. The company remains an active participant in the Southeast Asian healthcare market, leveraging its regional manufacturing capabilities to address infectious diseases and oncology.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Partnerships

CordlifeDNAPrint GenomicsPharsight

Beyond the preview

Go deeper on DNAPro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNAPro.

Explore the full profile